Skip to content
AnalystLens

Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2024

Filing Date
Filed October 30, 2024
Period End
September 30, 2024
Security
NBIX
One revenue dollarkept$0.21
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-Q filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported third-quarter 2024 results in its Form 10-Q for the period ended September 30, 2024.

Net product sales were $616.6 milliona for the quarter, up from $491.8 million a year earlier, and INGREZZA net product sales were $612.9 million. Net income rose to $129.8 million from $83.1 million, and diluted EPS was $1.24 versus $0.82. For the first nine months, total revenues were $1,727.6 million and net income was $238.2 million, compared with $102.0 million in the prior-year period.

Nine-month results were affected by $138.4 millionb of charges tied to the May 2024 settlement of the 2024 convertible senior notes, and by $14.0 million of impairment charges on vacated leased office space. Leadership and pipeline developments were significant during the quarter. Kevin Gorman, Ph.D., retired as CEO effective October 11, 2024, and Kyle Gano, Ph.D., succeeded him and joined the Board.

The company announced positive Phase 2 topline data for NBI-1117568 in schizophrenia and for NBI-1065845 in major depressive disorder, and FDA accepted NDAs for crinecerfont in classic congenital adrenal hyperplasia with PDUFA dates of December 29 and December 30, 2024. The Phase 2 study of luvadaxistat did not meet its primary endpoint, and the company gave notice to terminate its license agreements with Takeda and Idorsia. At September 30, 2024, cash, cash equivalents and marketable securities totaled $1,871.9 millionc, and working capital was $1,446.9 million.

In October 2024 the Board authorized a share repurchase program of up to $300 milliond, to be executed through an accelerated share repurchase transaction subject to market conditions. The filing states that existing capital resources are sufficient for at least the next 12 months.

Key Highlights

  1. Net product sales of $616.6 million in Q3 2024, up from $491.8 million in Q3 2023; INGREZZA accounted for $612.9 million.
  2. Q3 2024 net income of $129.8 million (diluted EPS $1.24), versus $83.1 million (diluted EPS $0.82) in Q3 2023.
  3. Nine-month net income of $238.2 million, including $138.4 million of charges associated with convertible senior notes settled in May 2024.
  4. Cash, cash equivalents and marketable securities of $1,871.9 million at September 30, 2024, and working capital of $1,446.9 million.
  5. CEO transition: Kevin Gorman, Ph.D., retired October 11, 2024, and Kyle Gano, Ph.D., succeeded him.
  6. FDA accepted NDAs for crinecerfont in classic CAH with Priority Review; PDUFA target dates are December 29, 2024 (capsule) and December 30, 2024 (oral solution).
  7. Board authorized a share repurchase program of up to $300 million in October 2024, to be executed through an accelerated share repurchase transaction.

Follow one dollar

Of each $1.00 of revenue in Q3 FY2024, Neurocrine Biosciences kept $0.21.

  1. Revenue$622.1M100.0%
  2. Cost of revenue−$8.0M1.3%
  3. Gross profit$614.1M98.7%
  4. Operating costs−$430.3M69.2%
  5. Operating income$183.8M29.5%
  6. Interest, other & tax−$54.0M8.7%
  7. Net income$129.8M20.9%
Computed from 10-QQ3 FY2024filed October 30, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q3 FY2024 against Q3 FY2023

Line itemQ3 FY2024Q3 FY2023Change
Revenue$622.10M$498.80M+24.7%
Cost of Revenue$8.00M$11.20M−28.6%
Gross Profit$614.10M$487.60M+25.9%
SG&A Expenses$234.30M$204.20M+14.7%
Operating Expenses$438.30M$357.60M+22.6%
Operating Income$183.80M$141.20M+30.2%
Net Income$129.80M$83.10M+56.2%
EPS (Basic)$1.28$0.85+50.6%
EPS (Diluted)$1.24$0.82+51.2%
Shares Outstanding (Basic)101.10M97.90M+3.3%
Shares Outstanding (Diluted)104.30M101.10M+3.2%

Frequently Asked Questions

  1. What drove revenue growth in the quarter?

    The filing attributes the increase in total net product sales for the first nine months of 2024 primarily to increased INGREZZA net product sales, driven by strong underlying patient demand and improved gross-to-net dynamics. Q3 2024 INGREZZA net product sales were $612.9 million, compared with $485.7 million in Q3 2023.

  2. Why did nine-month other expense increase?

    Total other expense, net, for the nine months was $105.1 million, compared with other income of $33.3 million a year earlier. The filing attributes the change primarily to $138.4 million of expense from conversions of the 2024 Notes upon maturity in May 2024, along with fluctuations in the fair value of equity investments, partially offset by higher interest income on debt securities.

  3. What is the status of the crinecerfont launch?

    The company announced that the FDA accepted NDAs for crinecerfont for pediatric and adult patients with classic congenital adrenal hyperplasia and granted Priority Review. The PDUFA target action dates are December 29, 2024 for the capsule formulation and December 30, 2024 for the oral solution formulation. The filing also notes pre-launch crinecerfont activities contributed to SG&A increases.

  4. What do the partner license terminations mean for the pipeline?

    The company gave Takeda written notice to terminate the license for luvadaxistat and NBI-1065846, effective April 2025 as anticipated, after the ERUDITE Phase 2 study of luvadaxistat did not meet its primary endpoint. It also gave Idorsia notice to terminate the license for NBI-827104, effective January 2025 as anticipated.